EPRX

Eupraxia Pharmaceuticals Inc

8.15

Nov 13 • 3:59 PM ET +0.34 (4.35%)

8.31

Aftermarket • 7:30 PM ET +0.16 (1.96%)

Healthcare Biotechnology Canada Small NASD

Peers: HRTX EYPT PCRX OCUL PYPD ANIK TARS UPB CNTB DWTX

Scroll to Statements

Index	-
Market Cap	548.01M
Enterprise Value	454.53M
Income	-61.48M
Sales	0.00M
Book/sh	1.36
Cash/sh	1.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	49
IPO	Aug 03, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.99
P/C	4.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.25
Current Ratio	12.25
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-1.03
EPS next Y	-1.05
EPS next Q	-0.27
EPS this Y	9.87%
EPS next Y	-13.32%
EPS next 5Y	-5.74%
EPS past 3/5Y	-2.38% -34.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	-18.46%
Sales Y/Y TTM	-
EPS Q/Q	-23.45%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	13.70% -

Insider Own	18.62%
Insider Trans	0.00%
Inst Own	42.85%
Inst Trans	2.47%
ROA	-52.06%
ROE	-55.97%
ROIC	-47.65%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.35%
SMA50	6.68%
SMA200	12.69%
Trades

Shs Outstand	67.24M
Shs Float	54.72M
Short Float	11.42%
Short Ratio	9.26
Short Interest	6.25M
52W High	9.32 -12.55%
52W Low	5.63 44.76%
Volatility	7.49% 7.15%
ATR (14)	0.53
RSI (14)	60.82
Beta	1.25
Rel Volume	1.15
Avg Volume	674.60K
Volume	777,252

Perf Week	18.29%
Perf Month	20.38%
Perf Quarter	19.50%
Perf Half Y	17.77%
Perf YTD	7.95%
Perf Year	28.55%
Perf 3Y	105.91%
Perf 5Y	262.22%
Perf 10Y	-
Recom	1.00
Target Price	16.66
Prev Close	7.81
Price	8.15
Change %	4.35%

Consensus

Strong Buy

Avg. Price Target

$16.66

Implied Upside

+104.4%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 09, 2026	Initiated	RRBC Capital Mkts	Outperform	$14	+71.8%
Sep 24, 2026	Initiated	WWedbush	Outperform	$17	+108.6%
Jun 26, 2026	Initiated	OOppenheimer	Outperform	$17	+108.6%
May 21, 2026	Initiated	SStifel	Buy	$25	+206.7%
Mar 23, 2026	Initiated	WWilliam Blair	Outperform
Jul 24, 2025	Initiated	CCantor Fitzgerald	Overweight	$11	+35.0%
Jun 26, 2025	Initiated	HH.C. Wainwright	Buy	$12	+47.2%
Jun 16, 2025	Initiated	CCanaccord Genuity	Speculative Buy
Feb 21, 2025	Initiated	CCraig Hallum	Buy	$12	+47.2%
Nov 14, 2024	Initiated	RRodman & Renshaw	Buy	$9	+10.4%

Nov-10-26 04:16PM	Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program (GlobeNewswire) +5.64%
04:01PM	Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-22-26 08:30AM	Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day (GlobeNewswire)
Oct-15-26 08:00AM	Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis (GlobeNewswire)
Oct-09-26 08:00AM	Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences (GlobeNewswire)
08:00AM	Loading…
Sep-30-26 08:00AM	Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis (GlobeNewswire) +9.57%
Sep-08-26 08:00AM	Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 08:00AM	Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients (GlobeNewswire)
Aug-11-26 05:21PM	Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-13-26 04:05PM	Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth (GlobeNewswire)
Jul-07-26 08:00AM	Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization (GlobeNewswire)
Jun-19-26 04:02PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders (GlobeNewswire)
May-28-26 08:00AM	Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 05:00PM	Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 07:00AM	Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (GlobeNewswire)
07:00AM	Loading…
May-05-26 07:00AM	Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) (GlobeNewswire)
May-01-26 05:05PM	Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer (GlobeNewswire) -5.96%
Apr-22-26 07:00AM	Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting (GlobeNewswire)
Apr-21-26 07:00AM	Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis (GlobeNewswire)
Apr-20-26 12:00AM	Upcoming Meeting Dates - April 20, 2026 (Newsfile)
Apr-13-26 08:00AM	Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-17-26 07:00AM	Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis (GlobeNewswire)
Mar-12-26 09:03PM	Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results (GlobeNewswire)
Feb-20-26 03:10PM	Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option (GlobeNewswire)
Feb-19-26 02:18AM	Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-18-26 04:01PM	Eupraxia Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Jan-08-26 01:10PM	Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus (Benzinga) +19.14%
07:34AM	Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy (GlobeNewswire)
Dec-04-25 10:09PM	Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why (Insider Monkey) +6.98%
Nov-14-25 09:55AM	Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet (Zacks)
05:00PM	Loading…
Nov-13-25 05:00PM	Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI (GlobeNewswire)
Nov-04-25 04:39PM	Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire) -10.51%
Oct-22-25 09:40AM	Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-14-25 12:00PM	Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy? (Zacks)
12:00PM	Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade (Zacks)
Sep-29-25 05:00PM	Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs (GlobeNewswire)
Sep-24-25 08:54AM	Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option (GlobeNewswire)
Sep-22-25 10:42PM	Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares (GlobeNewswire) +11.58% -14.89%
04:01PM	Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Sep-02-25 08:00AM	First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI (GlobeNewswire)
Aug-12-25 04:25PM	Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-22-25 05:17PM	Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences (GlobeNewswire)
Jul-08-25 07:00AM	Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis (GlobeNewswire)
Jun-02-25 06:30PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders (GlobeNewswire)
May-15-25 05:00PM	Bear-Pit Session Highlights Peterson Capitals Canada Growth Conference in Montreal (GlobeNewswire)
May-07-25 02:00PM	Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 (GlobeNewswire) -6.77%
May-06-25 06:00PM	Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 07:00AM	Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI (GlobeNewswire)
Apr-24-25 05:00PM	Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May (GlobeNewswire)
Mar-20-25 05:32PM	Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results (PR Newswire)
Feb-25-25 07:00AM	Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire) +10.28%
Feb-22-25 09:05AM	Craig-Hallum starts Eupraxia at Buy, sees significant upside potential (TipRanks)
Feb-18-25 07:00AM	Eupraxia Pharmaceuticals Announces CFO Succession (PR Newswire)
Nov-20-24 07:00AM	Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months (PR Newswire) +10.43%
Nov-14-24 05:00PM	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting (PR Newswire) +7.96%
Nov-13-24 05:00PM	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 (PR Newswire)
Nov-12-24 05:56PM	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
Nov-07-24 05:00PM	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-31-24 07:36PM	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million (PR Newswire)
Oct-28-24 07:00AM	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 (PR Newswire)
Oct-15-24 07:00AM	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis (PR Newswire)
Oct-10-24 07:00AM	Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 (PR Newswire)
Oct-02-24 05:01PM	Eupraxia Pharmaceuticals Strengthens Senior Management Team (PR Newswire)
Sep-19-24 05:00PM	Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases (PR Newswire)
Sep-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
Sep-04-24 07:00AM	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.77%
Aug-07-24 05:00PM	Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results (PR Newswire) +5.44%
Aug-02-24 07:00AM	Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility (PR Newswire) -10.14%
Jul-08-24 07:00AM	Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo (PR Newswire)
Jul-03-24 05:00PM	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024 (PR Newswire)
Jun-06-24 05:00PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders (PR Newswire)
Jun-05-24 07:00AM	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 (PR Newswire)
May-23-24 05:00PM	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ('EoE') on May 29, 2024 (PR Newswire)
May-21-24 05:00PM	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-14-24 07:00AM	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 (PR Newswire)
May-08-24 05:03PM	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 07:00AM	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board (PR Newswire)
Apr-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 (PR Newswire) -6.34%
Apr-08-24 07:00AM	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-05-24 07:00AM	Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today (PR Newswire)

Show Previous News

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

M.D.Dr. James A. Helliwell FRCPC

M.B.A.Mr. Alexander John Rothwell Eng.

M.Sc.Mr. Paul Anthony Brennan B.Sc.

CCPMs. Wajida Leclerc B.A.

Executive VP of R&DMr. Alex Therien

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

EPRX

Eupraxia Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.